LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Relay Therapeutics Inc

Închisă

SectorSănătate

2.79 -1.76

Rezumat

Modificarea prețului

24h

Curent

Minim

2.75

Maxim

2.87

Indicatori cheie

By Trading Economics

Venit

-1.1M

-77M

Vânzări

7.7M

7.7M

EPS

-0.455

Marjă de profit

-1,003.581

Angajați

259

EBITDA

-1.2M

-85M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+394.7% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-21M

533M

Deschiderea anterioară

4.55

Închiderea anterioară

2.79

Sentimentul știrilor

By Acuity

50%

50%

187 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Relay Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 mai 2025, 23:40 UTC

Acțiuni populare

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 mai 2025, 23:33 UTC

Principalele dinamici ale pieței

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 mai 2025, 23:25 UTC

Principalele dinamici ale pieței

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 mai 2025, 23:25 UTC

Câștiguri

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mai 2025, 22:58 UTC

Câștiguri

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 mai 2025, 21:35 UTC

Câștiguri

Cisco Systems Names Patterson as CFO, Patel as President

14 mai 2025, 23:59 UTC

Market Talk

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 mai 2025, 23:49 UTC

Market Talk

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 mai 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2025, 23:48 UTC

Market Talk

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 mai 2025, 23:47 UTC

Market Talk

Gold Gains on Possible Technical Recovery -- Market Talk

14 mai 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 mai 2025, 23:10 UTC

Câștiguri

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mai 2025, 23:07 UTC

Câștiguri

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 mai 2025, 23:00 UTC

Top știri

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 mai 2025, 22:43 UTC

Câștiguri

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 mai 2025, 22:34 UTC

Câștiguri

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 mai 2025, 22:33 UTC

Câștiguri

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 mai 2025, 22:30 UTC

Câștiguri

Xero Did Not Declare a Dividend>XRO.AU

14 mai 2025, 22:30 UTC

Câștiguri

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 mai 2025, 22:30 UTC

Câștiguri

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 mai 2025, 22:30 UTC

Câștiguri

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 mai 2025, 22:28 UTC

Câștiguri

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 mai 2025, 22:28 UTC

Câștiguri

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 mai 2025, 22:27 UTC

Câștiguri

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 mai 2025, 22:27 UTC

Câștiguri

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 mai 2025, 22:23 UTC

Top știri

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 mai 2025, 22:15 UTC

Câștiguri

Correction to Cisco Earnings Article -- WSJ

14 mai 2025, 21:48 UTC

Câștiguri

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 mai 2025, 21:37 UTC

Câștiguri

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Comparație

Modificare preț

Relay Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

394.7% sus

Prognoză pe 12 luni

Medie 14 USD  394.7%

Maxim 23 USD

Minim 4 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRelay Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

10

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.88 / 3.285Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

187 / 382 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.